ProstaGene was assigned important patents for cancer treatment.
US Patent issued September 27, 2016 as U.S. Patent No. 9,453,836. Use of modulators of CCR5 in the treatment of cancer and cancer metastasis” US Provisional Patent Application Nos. 61/646,593 and 61/646,586 (Reference Nos. 010236-5002-PR & 010236-5002-PR1)
http://patents.justia.com/inventor/richard-g-pestell

Categories: News